DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidDVTWells scoreD-dimerultrasoundDOAC

Deep vein thrombosis

Essential points for quick revision.

!
Escalate

DVT symptoms plus new breathlessness, chest pain, haemoptysis, syncope or haemodynamic compromise may indicate pulmonary embolism: activate the PE/emergency pathway rather than completing an isolated DVT work-up.

Synopsis

Apply the NICE two-level Wells pathway, avoid unsafe diagnostic delay and choose initial anticoagulation with UK-specific modifiers.

  • Use the 2-level DVT Wells score: 2 points or more means DVT likely; 1 point or less means DVT unlikely.
  • Likely DVT: obtain proximal leg-vein ultrasound within 4 hours if possible; if delayed, give interim therapeutic anticoagulation and scan within 24 hours.
  • Unlikely DVT: obtain D-dimer within 4 hours; if delayed, give interim therapeutic anticoagulation while awaiting the result.

Key red flags

Phlegmasia

Massive painful swelling, cyanosis, sensory/motor change or threatened perfusion from extensive venous occlusion requires emergency vascular/haematology assessment.

Investigation priorities

01
Two-level DVT Wells scoreFirst step

Set the NICE diagnostic pathway before testing.

Management branches

likelyWells score at least 2

Clinically suspected DVT with a likely 2-level Wells score.

  1. First: proximal leg-vein ultrasound with result within 4 hours if possible.
  2. Next: if ultrasound cannot be obtained within 4 hours, take D-dimer, give interim therapeutic anticoagulation and obtain ultrasound within 24 hours.
special groupsChoice modifiers

A condition that makes routine DOAC treatment uncertain or unsuitable.

Key medicines

Apixaban10 mg orally twice daily for 7 days, then 5 mg twice daily; if extended prevention is chosen after 6 months, 2.5 mg twice daily.
Rivaroxaban15 mg orally twice daily with food for 21 days, then 20 mg once daily with food; after at least 6 months, 10 mg once daily (or 20 mg once daily if recurrence risk is high).
Open full textbook Answer 2 questionsCardiology check
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom